This work highlights that the existence of CD8+ T-cell subsets with dual and triple co-inhibitory receptor expression requires the use of multiple checkpoint-targeted agents to overcome T-cell dysfunction in ovarian cancer [11]. The gene discussed is CD8A; the disease is ovarian cancer.